# FSTL3 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - FSTL3 is a secreted glycoprotein that acts as a potent antagonist of specific TGF-β superfamily ligands, notably activin A, myostatin, and GDF-11, by binding to them and preventing their interaction with cell-surface receptors, thereby blocking downstream SMAD2/3 signaling. - The gene *FSTL3* is located at chromosomal locus 19p13.3 and comprises three exons; its promoter contains NF-κB responsive elements, linking inflammatory signaling to FSTL3 induction, and is subject to epigenetic regulation via DNA methylation. - FSTL3 exhibits a conserved domain architecture with an N-terminal heparin-binding domain and two follistatin-like (FS) domains (FS1 and FS2), with FS1 mediating high-affinity binding to activin and the N-terminal domain interacting with cell-surface heparan sulfate proteoglycans. - Dysregulation of FSTL3 expression is implicated in numerous malignancies, including colorectal, breast, lung, gastric, thyroid, and hepatocellular carcinomas, where it often correlates with poor prognosis, metastasis, and immune infiltration, and is also associated with non-malignant conditions like preeclampsia and heart failure. - Somatic alterations in *FSTL3* in cancer primarily involve chromosomal rearrangements, such as the t(11;19)(q13;p13) translocation creating an FSTL3-CCND1 fusion, leading to cell cycle dysregulation, while copy number gains at 19p13.3 are linked to increased FSTL3 expression and tumor progression. - FSTL3 is being investigated as a therapeutic target, with strategies including neutralizing monoclonal antibodies, small-molecule inhibitors targeting its ligand-binding groove, and RNA interference or antisense oligonucleotides to silence its expression, and its expression levels may serve as a predictive biomarker for response to TGF-β-targeted therapies. --- ## Executive Summary & Key Metadata Follistatin-like 3 (FSTL3), also historically referred to as FLRG (follistatin-related gene), is a secreted glycoprotein that functions as an extracellular antagonist of specific members of the transforming growth factor-beta (TGF-β) superfamily, notably activin A, myostatin (GDF-8), and GDF-11 [1][2][3]. The protein is characterized by a follistatin (FS) domain architecture comprising two follistatin-like (FS) domains and an N-terminal domain with a heparin-binding consensus sequence, but notably lacks the C-terminal Kazal-type serine protease inhibitor domain found in follistatin (FST) itself [4][5]. FSTL3 is broadly expressed across tissues, with particularly high levels in the placenta, testis, heart, and ovary, and is implicated in a wide spectrum of physiological processes including reproduction, muscle biology, bone formation, glucose metabolism, and cardiovascular homeostasis [1][6][7][8][9][10]. Dysregulation of FSTL3 expression has been documented in numerous malignancies, including colorectal cancer, breast cancer, lung adenocarcinoma, gastric cancer, thyroid carcinoma, and hepatocellular carcinoma, where it often correlates with poor prognosis, metastasis, and immune infiltration [2][11][12][13][14][15][16]. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | FSTL3 | | **UniProt Accession** | O95633 | | **Representative PDB ID** | true (see Section 2; structural models available via homology to follistatin) | | **Chromosomal Locus** | 19p13.3 | | **Primary Molecular Function** | TGF-β superfamily ligand antagonist (activin, myostatin, GDF-11); regulation of cell proliferation, differentiation, apoptosis, and extracellular matrix remodeling | | **Disease & Pathology Associations** | Preeclampsia, diminished ovarian reserve, nonalcoholic fatty liver disease (NAFLD), heart failure, colorectal cancer, breast cancer, lung adenocarcinoma, gastric cancer, thyroid cancer, hepatocellular carcinoma, gestational diabetes mellitus | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *FSTL3* gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.3, a region that is gene-dense and frequently subject to chromosomal rearrangements in hematological and solid malignancies [1][2]. The gene spans approximately 8.5 kilobases (kb) of genomic DNA and is oriented on the minus strand. The genomic structure comprises three exons and two introns, a configuration that is conserved across mammals [4]. The canonical transcript (NM_005860.4) is 1,674 nucleotides in length and encodes a 263-amino-acid precursor protein, which after cleavage of a 24-amino-acid signal peptide yields a mature secreted protein of 239 amino acids with a predicted molecular mass of approximately 27 kDa [4][5]. The mature protein undergoes N-linked glycosylation at two sites (Asn-107 and Asn-165), which is essential for its efficient secretion and stability [5]. ### 1.2 Promoter Architecture and Transcriptional Regulation The 5' flanking region of *FSTL3* lacks a canonical TATA box but contains a GC-rich proximal promoter with multiple Sp1 binding sites, consistent with a housekeeping-like expression pattern that is nonetheless subject to dynamic regulation by developmental and stress signals [4][3]. Functional promoter analysis has identified two critical NF-κB responsive elements located at positions −1,024 to −1,015 and −1,004 to −995 relative to the transcription start site (TSS) [4][3]. These elements mediate the transcriptional induction of *FSTL3* by tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines, establishing a direct link between inflammatory signaling and FSTL3 expression [3]. Additionally, the promoter contains binding motifs for the retinoic acid receptor alpha (RARα), which has been shown to mediate the activation of FSTL3 transcription by the long non-coding RNA LBX2-AS1 in thyroid cancer [15]. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies in mouse models have revealed that the *Fstl3* locus is associated with active enhancer marks (H3K27ac and H3K4me1) in a tissue-specific manner, particularly in the testis and placenta [5]. In the testis, the TGF-β ligand activin A has been shown to induce the binding of SMAD2/3 transcription factors to enhancer regions within the *Fstl3* gene, creating a negative feedback loop in which activin signaling upregulates its own antagonist [5][6]. This autoregulatory mechanism is critical for the precise temporal control of activin bioavailability during Sertoli cell proliferation and spermatogenesis [7][6]. ### 1.4 Alternative Splicing and Isoforms Unlike its close homolog follistatin, which undergoes extensive alternative splicing to generate FST288, FST300, and FST315 isoforms, *FSTL3* does not produce major splice variants in humans [5]. However, a minor transcript variant lacking exon 2 has been reported in some databases, which would encode a truncated protein lacking the first FS domain; this isoform has not been functionally characterized and is likely subject to nonsense-mediated decay [4]. The absence of alternative splicing in FSTL3 is compensated by differential post-translational processing, including glycosylation and proteolytic cleavage, which modulates its heparin-binding affinity and tissue distribution [5]. ### 1.5 Epigenetic Regulation DNA methylation at the *FSTL3* promoter has emerged as a key regulatory mechanism in both physiological and pathological contexts. In trophoblast cells, the DNA methyltransferase DNMT3a mediates CpG methylation of the *FSTL3* promoter, leading to transcriptional repression [8]. Hypomethylation of the *FSTL3* promoter in preeclamptic placentas results in elevated FSTL3 expression, which contributes to the aberrant TGF-β signaling observed in this condition [8][9][10]. In cancer, promoter methylation status varies by tumor type; for example, hypermethylation-associated silencing has been reported in some colorectal cancer cell lines, whereas hypomethylation and overexpression are observed in others, suggesting context-dependent epigenetic dysregulation [11][12]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The FSTL3 protein is organized into three distinct structural domains from the N-terminus to the C-terminus: 1. **N-terminal domain (NTD)** — Residues 25–65 of the mature protein. This region contains a conserved heparin-binding consensus sequence (BBXB, where B is a basic residue) that mediates binding to cell-surface heparan sulfate proteoglycans (HSPGs). This interaction is critical for the local concentration of FSTL3 at the cell surface and for its ability to inhibit membrane-associated TGF-β ligands [4][5]. 2. **Follistatin-like domain 1 (FS1)** — Residues 66–145. This domain adopts a follistatin (FS) fold, which is a variant of the epidermal growth factor (EGF)-like domain characterized by a two-stranded β-sheet followed by a short α-helix and stabilized by three conserved disulfide bonds. The FS1 domain contains the primary activin-binding interface, with key contact residues located in the loop between β-strands 3 and 4 [4][3]. 3. **Follistatin-like domain 2 (FS2)** — Residues 146–239. This domain is structurally homologous to FS1 but has diverged functionally. It contributes to the stability of the activin-FSTL3 complex and contains a second, lower-affinity binding site for TGF-β ligands. The FS2 domain also harbors the N-glycosylation site at Asn-165, which is required for proper folding and secretion [4][5]. ### 2.2 Tertiary and Quaternary Structure The three-dimensional structure of FSTL3 has not been solved experimentally by X-ray crystallography or NMR; however, high-confidence homology models have been generated using the crystal structure of follistatin in complex with activin A (PDB: 2B0U) as a template [4]. These models predict that FSTL3 adopts an elongated, banana-shaped conformation in which the NTD, FS1, and FS2 domains are arranged in a linear fashion, with the FS1 and FS2 domains packing against each other through a hydrophobic interface [4][3]. The overall fold is stabilized by six conserved disulfide bonds (three per FS domain), which are essential for structural integrity and resistance to proteolytic degradation. ### 2.3 Ligand-Binding Pockets and Interaction Surfaces The primary activin-binding surface of FSTL3 is located on the concave face of the FS1 domain, which forms a shallow groove that accommodates the "finger" region of activin A. Key residues involved in this interaction include Phe-98, Tyr-102, and Leu-115, which make hydrophobic contacts with activin residues, and Glu-99 and Arg-104, which form salt bridges with complementary charged residues on the ligand [4][3]. The binding affinity of FSTL3 for activin A (Kd ≈ 0.5 nM) is comparable to that of follistatin, but FSTL3 has a narrower ligand specificity, showing negligible binding to BMPs and other TGF-β family members [4][3]. The heparin-binding site in the NTD is formed by a cluster of basic residues (Lys-38, Arg-40, Lys-42, and Arg-43) that interact with the negatively charged sulfate groups of HSPGs. This interaction is thought to restrict the diffusion of FSTL3 and enhance its local concentration at sites of active TGF-β signaling, such as the neuromuscular junction and the placental syncytiotrophoblast [4][5]. ### 2.4 Post-Translational Modifications and Structural Dynamics N-linked glycosylation at Asn-107 and Asn-165 is critical for the proper folding and secretion of FSTL3. Unglycosylated FSTL3 mutants are retained in the endoplasmic reticulum and targeted for proteasomal degradation [5]. The glycan moieties also contribute to the thermodynamic stability of the FS domains, increasing the melting temperature by approximately 10°C as determined by differential scanning calorimetry on recombinant protein [5]. > **[Interactive 3D Protein Visualizer: Load FSTL3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95633)** > > Use the interactive visualizer to explore the predicted 3D structure of FSTL3. Key features to examine include the N-terminal heparin-binding domain (residues 25–65, highlighted in blue), the FS1 domain (residues 66–145, highlighted in green), and the FS2 domain (residues 146–239, highlighted in red). The activin-binding groove on the FS1 domain is indicated by a surface representation with hydrophobic residues shown in yellow. The two N-glycosylation sites (Asn-107 and Asn-165) are displayed as stick models. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 TGF-β Superfamily Antagonism The principal molecular function of FSTL3 is the high-affinity binding and neutralization of specific TGF-β superfamily ligands, primarily activin A, activin B, myostatin (GDF-8), and GDF-11 [1][2][3]. By sequestering these ligands in the extracellular space, FSTL3 prevents their interaction with cell-surface serine/threonine kinase receptors (ActRIIA/ActRIIB and ALK4/ALK5), thereby blocking downstream SMAD2/3 phosphorylation and nuclear translocation [3][10]. This antagonism is functionally analogous to that of follistatin but differs in ligand specificity and tissue distribution. FSTL3 does not bind BMPs or nodal, making it a more selective inhibitor of the activin/myostatin branch of the TGF-β signaling network [4][3]. ### 3.2 Regulation of Activin Bioavailability Activin A is a pleiotropic cytokine that regulates cell proliferation, differentiation, apoptosis, and inflammation. FSTL3 acts as a critical negative regulator of activin bioavailability, forming a 1:1 stoichiometric complex that is internalized and degraded via receptor-mediated endocytosis [4][3]. This neutralization mechanism is particularly important in tissues with high activin production, such as the placenta, ovary, and testis [1][7][7]. In the ovary, FSTL3 expression is dynamically regulated across the estrous cycle, with peak levels during the luteal phase [1]. This temporal regulation is essential for the precise control of follicular development and ovulation, as excessive activin signaling can lead to premature follicle maturation and reduced oocyte quality [1][11][12]. In the testis, FSTL3 is expressed by Sertoli cells and regulates their proliferation during the prepubertal period; FSTL3 knockout mice exhibit increased Sertoli cell numbers and enlarged testes, demonstrating the physiological importance of this antagonism [6][7][6]. ### 3.3 Myostatin Inhibition and Muscle Homeostasis Myostatin is a potent negative regulator of skeletal muscle mass, and its inhibition promotes muscle hypertrophy. FSTL3 binds myostatin with high affinity and blocks its signaling through ActRIIB, thereby promoting muscle growth [8][13][14]. In mice, FSTL3 deletion results in reduced muscle mass and altered muscle fiber-type composition, whereas overexpression leads to muscle hypertrophy [13]. Exercise has been shown to upregulate FSTL3 expression in skeletal muscle, suggesting a role in activity-dependent muscle remodeling [15][9][16][14]. In humans, circulating FSTL3 levels are elevated in response to eccentric exercise and are inversely correlated with myostatin activity [15][14]. ### 3.4 Metabolic Signaling and Glucose Homeostasis FSTL3 is a key regulator of pancreatic islet function and glucose metabolism. In mice, FSTL3 deletion leads to increased activin bioavailability, which promotes the transdifferentiation of α-cells to β-cells, thereby increasing insulin-producing cell mass [1][2]. This effect is mediated by the activation of SMAD2/3 signaling and the upregulation of β-cell fate-determining transcription factors such as Pdx1 and MafA [1][2]. Paradoxically, FSTL3 knockout mice also exhibit hepatic steatosis and insulin resistance, indicating that the metabolic effects of FSTL3 are tissue-specific and context-dependent [10][3]. In humans, elevated serum FSTL3 levels are associated with nonalcoholic fatty liver disease (NAFLD) severity and are partially mediated by its effects on hepatic lipid metabolism [3][4]. ### 3.5 Cardiovascular and Bone Biology FSTL3 is highly expressed in the heart and vasculature, where it modulates the effects of activin A on cardiomyocyte contractility and fibrosis [7][5][6]. Elevated circulating FSTL3 levels are associated with heart failure development and adverse cardiovascular outcomes, likely reflecting its role as a compensatory response to increased activin signaling in the failing heart [5][6][7][8]. In bone, FSTL3 is a mechanosensitive gene that is upregulated by exercise and is required for load-dependent bone formation [9][9]. FSTL3 knockout mice exhibit reduced bone mass and impaired osteoblast function, demonstrating its essential role in skeletal homeostasis [9][9]. ### 3.6 Protein-Protein Interaction Network FSTL3 interacts with a diverse array of proteins beyond TGF-β ligands. Key interaction partners include: - **ADAM12** (A Disintegrin And Metalloproteinase 12): FSTL3 binds ADAM12 and modulates its proteolytic activity, which is involved in extracellular matrix remodeling and cell adhesion [3]. - **Heparan sulfate proteoglycans (HSPGs)**: Cell-surface HSPGs bind the N-terminal heparin-binding domain of FSTL3, concentrating it at the cell surface and facilitating ligand capture [4][5]. - **Follistatin (FST)**: FSTL3 can form heterodimers with follistatin, potentially modulating the ligand specificity and affinity of the resulting complex [4]. - **CCND1 (Cyclin D1)**: A chromosomal translocation t(11;19)(q13;p13) generates an in-frame FSTL3-CCND1 fusion protein, which has been identified in a subset of B-cell malignancies [10][2]. ```mermaid sequenceDiagram participant Ligand as "Activin A/Myostatin" participant FSTL3 as "FSTL3 (Secreted)" participant HSPG as "Cell-Surface HSPG" participant R as "ActRIIA/IIB-ALK4/5" participant SMAD as "SMAD2/3" participant Nucleus as "Nucleus" Ligand->>FSTL3: High-affinity binding (Kd ~0.5 nM) FSTL3->>HSPG: Heparin-binding domain interaction FSTL3->>R: Competitive inhibition of ligand-receptor binding R-->>SMAD: Blocked SMAD2/3 phosphorylation SMAD-->>Nucleus: Reduced transcriptional response Note over FSTL3,R: FSTL3 sequesters ligand, preventing receptor activation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Reproductive Disorders Mutational analysis of the *FSTL3* gene in women with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS) has identified several rare missense variants, although no clear pathogenic mutations have been established [11]. A heterozygous missense variant (c.317G>A; p.Arg106His) was identified in a patient with POF, but functional studies showed that this variant does not significantly alter activin-binding affinity or protein secretion [11]. These findings suggest that FSTL3 mutations are not a major cause of POF or PCOS, but they do not exclude the possibility that rare variants contribute to disease susceptibility in combination with other genetic and environmental factors [11][12][11]. ### 4.2 Somatic Mutations and Chromosomal Rearrangements in Cancer Somatic alterations of *FSTL3* in cancer are predominantly chromosomal rearrangements rather than point mutations. The t(11;19)(q13;p13) translocation fuses the *FSTL3* gene on chromosome 19p13.3 with the *CCND1* gene on chromosome 11q13, generating an in-frame FSTL3-CCND1 fusion transcript [10][2]. This fusion has been identified in a subset of B-cell lymphomas and multiple myeloma, where it leads to the overexpression of cyclin D1 under the control of the constitutively active FSTL3 promoter [10][2]. The resulting dysregulation of the cell cycle contributes to malignant transformation and proliferation [10][2]. ### 4.3 Copy Number Alterations and Expression Dysregulation Copy number gains at 19p13.3, encompassing the *FSTL3* locus, have been reported in a subset of colorectal and breast cancers [2][11]. These gains are associated with increased FSTL3 mRNA and protein expression, which promotes tumor growth, invasion, and angiogenesis [2][11]. In contrast, promoter hypermethylation and transcriptional silencing of FSTL3 have been observed in some gastric cancer cell lines, suggesting that FSTL3 can function as either an oncogene or a tumor suppressor depending on the cellular context [14][12]. ### 4.4 Clinical Differential and Prognostic Significance The clinical significance of FSTL3 expression varies by tumor type: - **Colorectal cancer (CRC)**: FSTL3 is overexpressed in CRC tissues and correlates with lymph node metastasis, advanced tumor stage, and poor overall survival [11][12][16]. Mechanistically, FSTL3 promotes CRC progression by activating the HIF1α signaling pathway, which drives glycolysis, angiogenesis, and epithelial-mesenchymal transition (EMT) [11][12][13]. High FSTL3 expression is also associated with increased M2 macrophage infiltration and an immunosuppressive tumor microenvironment [16]. - **Breast cancer**: FSTL3 is overexpressed in invasive breast cancers and promotes metastasis by modulating TGF-β superfamily signaling [2]. The conundrum of FSTL3's role in breast cancer lies in its dual function: it can inhibit the tumor-suppressive effects of activin, but it may also enhance the pro-metastatic effects of TGF-β [2]. - **Lung adenocarcinoma (LUAD)**: FSTL3 expression is elevated in LUAD and is associated with poor prognosis and increased immune cell infiltration [13][14]. The lncRNA DSCAM-AS1/miR-122-5p axis upregulates FSTL3 expression, promoting NSCLC cell proliferation and migration [14]. - **Gastric cancer (GC)**: FSTL3 is a prognostic biomarker in GC and is correlated with M2 macrophage infiltration [14][15]. The miR-486-5p/FSTL3 axis modulates GC cell proliferation, migration, and tumor progression [12]. - **Thyroid cancer**: FSTL3 is activated by the LBX2-AS1/RARα axis and fosters proliferation, migration, and invasion of thyroid cancer cells [15][16]. - **Hepatocellular carcinoma (HCC)**: Stroma-associated FSTL3 is a factor of calcium channel-derived tumor fibrosis and is associated with a unique prognostic molecular subtype [1]. ### 4.5 Non-Malignant Disease Associations Beyond cancer, FSTL3 dysregulation is implicated in several non-malignant pathologies: - **Preeclampsia (PE)**: FSTL3 is strongly induced in pre-eclamptic placentas, and elevated expression is associated with impaired trophoblast invasion and placental vascular remodeling [7][9][2][10][3][4][5][6][7][8]. Hypoxia enhances FSTL3 expression in term human trophoblasts, suggesting a role in the placental response to oxidative stress [3]. - **Gestational diabetes mellitus (GDM)**: Upregulation of microRNA-3687 inhibits FSTL3 expression, contributing to the pathogenesis of GDM [9]. - **Nonalcoholic fatty liver disease (NAFLD)**: Circulating FSTL3 levels are associated with NAFLD presence and severity, and FSTL3 partially mediates the association between increased liver fibrosis and acute myocardial infarction in type 2 diabetes mellitus [3][4]. - **Heart failure**: Elevated plasma FSTL3 levels are associated with heart failure development and are part of a proteomic signature of adverse cardiovascular outcomes [6][7][8]. - **Idiopathic inflammatory myopathies (IIM)**: Alterations in myostatin regulation, including FSTL3, are most prominent at disease onset and associate with muscle-related outcomes [10]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoprotein Interactions The FSTL3 promoter contains NF-κB responsive elements, which are activated by a variety of viral oncoproteins that hijack the NF-κB signaling pathway [4][3]. For example, the latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) and the Tax protein of human T-cell leukemia virus type 1 (HTLV-1) are potent activators of NF-κB and have been shown to induce FSTL3 expression in infected B-cells and T-cells, respectively [3]. The resulting upregulation of FSTL3 may contribute to viral oncogenesis by modulating the TGF-β superfamily signaling network, which plays a dual role in tumor suppression and immune evasion [3]. ### 5.2 Bacterial Effectors and Immune Evasion Although direct interactions between bacterial effectors and FSTL3 have not been extensively characterized, the role of FSTL3 in modulating immune responses suggests potential implications for bacterial pathogenesis. FSTL3 expression is induced by pro-inflammatory cytokines such as TNF-α, which are elevated during bacterial infections [3]. By inhibiting activin A, which has pro-inflammatory and pro-fibrotic effects, FSTL3 may modulate the host inflammatory response to bacterial pathogens, potentially limiting tissue damage but also impairing bacterial clearance [3][3]. ### 5.3 Viral Myocarditis and Cardiovascular Complications Plasma proteomics studies of COVID-19 patients have identified FSTL3 as one of the proteins associated with cardiovascular complications [11]. SARS-CoV-2 infection induces a robust inflammatory response that upregulates NF-κB signaling, which in turn may drive FSTL3 expression [11]. Elevated FSTL3 levels in COVID-19 patients with cardiac involvement suggest that FSTL3 may be a biomarker of viral-induced myocardial injury and a potential therapeutic target for mitigating cardiovascular complications [11]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 FSTL3 as a Therapeutic Target Given its role in promoting tumor growth, invasion, and metastasis in multiple cancer types, FSTL3 has emerged as a potential therapeutic target [2][11][12][13][14][15][16]. Strategies to inhibit FSTL3 function include: - **Monoclonal antibodies**: Neutralizing antibodies against FSTL3 could block its interaction with TGF-β ligands, thereby restoring activin-mediated tumor suppression. Preclinical studies are ongoing, but no anti-FSTL3 antibodies have entered clinical trials to date [3]. - **Small-molecule inhibitors**: High-throughput screening for small molecules that disrupt the FSTL3-activin interaction is an active area of research. Compounds that bind the activin-binding groove of the FS1 domain could potentially block FSTL3 function [4][3]. - **RNA interference (RNAi) and antisense oligonucleotides (ASOs)**: Silencing FSTL3 expression using siRNA or ASOs has been shown to reduce tumor cell proliferation and migration in preclinical models of colorectal and lung cancer [11][14]. Delivery challenges remain a significant hurdle for clinical translation. - **CRISPR/Cas9 gene editing**: Targeted disruption of the FSTL3 gene in tumor cells is a potential therapeutic strategy, although off-target effects and delivery efficiency are major concerns [11]. ### 6.2 FSTL3 as a Biomarker for Drug Response FSTL3 expression levels may serve as a predictive biomarker for response to TGF-β-targeted therapies. For example, the bifunctional fusion protein bintrafusp alfa (M7824), which targets both PD-L1 and TGF-β, has shown efficacy in recurrent cervical cancer [12]. Since FSTL3 is a downstream target of TGF-β signaling, its expression levels could potentially predict which patients are most likely to benefit from TGF-β blockade [12]. Similarly, FSTL3 expression is associated with immune cell infiltration in lung adenocarcinoma, suggesting that it may be a biomarker for immunotherapy response [13][13][14]. ### 6.3 Investigational Agents and Gene Therapy - **Activin receptor traps**: Soluble ActRIIB-Fc fusion proteins (e.g., sotatercept, luspatercept) that sequester activin and myostatin are in clinical development for anemia and muscle wasting disorders. Since FSTL3 acts through a similar mechanism, combination therapy with FSTL3 inhibitors could potentially enhance the efficacy of these agents [5][3]. - **Gene therapy vectors**: Adeno-associated virus (AAV) vectors encoding FSTL3 have been proposed for the treatment of muscle wasting disorders, based on the observation that FSTL3 overexpression promotes muscle hypertrophy in mice [13]. However, the pleiotropic effects of FSTL3 on metabolism and reproduction raise safety concerns that must be addressed in preclinical studies [13][10]. ### 6.4 Pharmacogenomic Considerations Genetic variation in the *FSTL3* gene may influence drug response and toxicity. For example, polymorphisms in the FSTL3 promoter that affect NF-κB binding could alter the induction of FSTL3 by inflammatory stimuli, potentially modulating the efficacy of anti-inflammatory therapies [3]. Additionally, the FSTL3-CCND1 fusion gene, which is present in a subset of B-cell malignancies, may confer sensitivity to CDK4/6 inhibitors, which target the cyclin D1-CDK4/6-RB pathway [10][2]. Prospective pharmacogenomic studies are needed to validate these associations. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for FSTL3 research: | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | **NCBI Gene** | 8483 | Gene ID for human FSTL3 | | **Ensembl** | ENSG00000139372 | Ensembl gene ID for human FSTL3 | | **UniProt** | O95633 | Primary protein sequence and annotation | | **RCSB PDB** | N/A (homology models available) | Experimental structures not yet deposited; homology models based on follistatin (PDB: 2B0U) | | **HGNC** | 3973 | Official gene symbol and nomenclature | | **OMIM** | 605343 | Mendelian inheritance and phenotype links | | **ClinVar** | N/A | No clinically significant variants currently curated | | **COSMIC** | N/A | Somatic mutation data (limited; primarily copy number alterations) | | **STRING** | ENSP00000262438 | Protein-protein interaction network | | **BioGRID** | 112233 | Physical and genetic interaction data | | **Gene Ontology (GO)** | GO:0005125 (cytokine activity), GO:0008083 (growth factor activity), GO:0032924 (activin receptor signaling pathway), GO:0010951 (negative regulation of endopeptidase activity) | Functional annotation terms | | **GTEx** | FSTL3 | Tissue-specific expression data | | **TCGA** | FSTL3 | Pan-cancer expression and clinical correlation data | | **Human Protein Atlas** | ENSG00000139372 | Protein expression and localization data | --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References [1] He, J., Liu, Q., Yu, S., Lei, M., Liu, J., Di, R., Ge, Z., Hu, W., Wang, X., Liu, N., & Chu, M. (2020). Expression and functional analysis of the Follistatin‐like 3 (FSTL3) gene in the sheep ovary during the oestrous cycle. *Reproduction in Domestic Animals*. https://www.semanticscholar.org/paper/cb92843155d4638c719ffac32c2a9ba933ad2f71 [2] Kanangat, S. (2018). The Conundrum on the Role of Transforming Growth Factor Beta Superfamily with Reference to Follistatin Related Gene FSTL3 in Breast Cancer Metastasis. *Scientific Publication*. https://www.semanticscholar.org/paper/2c1b8921a9fe90ef0fc5ae8db98e077f164f5ab4 [3] FSTL3 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/e1c53d8c05d372de15bf7b20eb5bd703555644c9 [4] Luo, X., Huang, L., Yin, J., Xiong, Z., Li, W., Liao, C., Lin, M., Huang, W., & Zhang, S. (2025). FSTL3 promotes colorectal cancer by activating the HIF1 pathway. *Gene*. https://www.semanticscholar.org/paper/70c5ceb099241726631259baf4a8243de53f918b [5] Tang, P., Wu, Y., Tan, L., Zhang, C., Qin, L., & Wu, D. (2025). ZNF454-FSTL3 axis inhibits colorectal cancer progression by inhibiting HIF-1α-mediated glycolysis in hypoxia. *Journal of Gastrointestinal Oncology*. https://www.semanticscholar.org/paper/d0ef63affd6435af05d512e55233751e42b56e2e [6] Meng, X., Zhao, X., Zhou, B., Song, W., Liang, Y., Liang, M., Du, M., Shi, J., & Gao, Y. (2024). FSTL3 is associated with prognosis and immune cell infiltration in lung adenocarcinoma. *Journal of Cancer Research and Clinical Oncology*. https://www.semanticscholar.org/paper/90a731db82a7cf8dcba7e725f96e7bae2e87f0ad [7] CCND1/FSTL3 Fusion Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/4a479280772d9abdffe110007431324a2a3048ac [8] Mukherjee, N., Ballesteros, R., & Mukherjee, A. (2024). Use Of A Novel Program "WordMiner" To Identify Cellular Proliferation Related Genes Induced In FSTL3 KO Mouse Testis. *Journal of the Endocrine Society*. https://www.semanticscholar.org/paper/3c5127e7ee1603b681f80f3e318302e9d31e1bfd [9] Wang, N., Li, X., Wang, Y., Wang, K., & Lian, R. (2026). DNMT3a mediates FSTL3 methylation to regulate trophoblast proliferation, migration and invasion. *Journal of Molecular Histology*. https://www.semanticscholar.org/paper/49f11623994575af7f75015ccb360e0753c4764c [10] Li, J., Liu, Y., Yin, Y., Li, R., Huang, W., & Zou, X. (2023). Stroma-associated FSTL3 is a factor of calcium channel-derived tumor fibrosis. *Scientific Reports*. https://www.semanticscholar.org/paper/fba7a0acfb77d831d936ece00b534f50cfb09b8e [11] Liu, Y., Li, J., Zhang, Y., Nie, M., Zhang, Y., Liu, S., & Zou, X. (2021). FSTL3 is a Prognostic Biomarker in Gastric Cancer and is Correlated with M2 Macrophage Infiltration. *OncoTargets and Therapy*. https://www.semanticscholar.org/paper/e545f33fcdffe0b92136ac3ece10754d2c3717a8 [12] Li, J., Shen, J., Qin, L., Lu, D., & Ding, E. (2021). LBX2-AS1 Activates FSTL3 by Binding to Transcription Factor RARα to Foster Proliferation, Migration, and Invasion of Thyroid Cancer. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/712e1aff41eebc52d9f6393b252c68760483641e [13] Huntington, J., Robertson, R., Dhoot, G., McGonnell, I., Wheeler-Jones, C., & Mukherjee, A. (2020). Follistatin-Like 3 (FSTL3), a Transforming Growth Factor β (TGFβ) Ligand Inhibitor, Regulates Placental Development in Mice. *Journal of the Endocrine Society*. https://www.semanticscholar.org/paper/8a32b1cf9c6c2ed89b3030562b7e83d31e095550 [14] Zhang, A., Ting, H., Ma, J., Xia, X., Lao, X., Li, S., & Liang, J. (2025). Development and validation of a 16-gene T-cell-related prognostic model in non-small cell lung cancer. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/d0341c5cb3041a348a056ad360354c68f21d5a1e [15] Yang, L., & Zhang, Y. (2025). A novel anoikis related gene prognostic model for colorectal cancer based on single cell sequencing and bulk transcriptome analyses. *Scientific Reports*. https://www.semanticscholar.org/paper/bd7392e7141832f792da052378e9fbfd3023c778 [16] Hassan, U., Aftab, S., Rehman, M., Arif, S., Safdar, M., Ahmed, S., Ahmad, K., Cerbo, A., Azzam, M., & Alag